Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis
暂无分享,去创建一个
Roberta Lazzari | Vincenzo Baldo | Tatjana Baldovin | Maria Carrara | M. Carrara | A. Floreani | V. Baldo | T. Baldovin | D. Gabbia | Annarosa Floreani | Daniela Gabbia | Arianna Dalla Pozza | Laura Albertoni | Giorgia Zigiotto | Sara De Martin | R. Lazzari | L. Albertoni | G. Zigiotto | A. D. Pozza
[1] J. Staudinger,et al. Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver , 2013, Drug metabolism reviews.
[2] M. Trauner,et al. Nuclear receptors as new perspective for the management of liver diseases. , 2011, Gastroenterology.
[3] P. Thomas,et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[4] R. Poupon. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.
[5] V. Ling,et al. Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep−/− mice , 2014, Molecular and Cellular Biochemistry.
[6] E. Gonzalez-Sanchez,et al. Nuclear Receptors in Acute and Chronic Cholestasis , 2015, Digestive Diseases.
[7] A. Mendeloff. Chronic liver disease. , 1956, Sinai Hospital journal.
[8] K. Byth,et al. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. , 1995, Biochemical pharmacology.
[9] M. Downes,et al. FXR and PXR: Potential therapeutic targets in cholestasis , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[10] M. Ene,et al. Pharmacokinetics of Nifedipine After Oral Administration in Chronic Liver Disease , 1987, Journal of clinical pharmacology.
[11] G. Farrell,et al. Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: Relevance to drug metabolism in experimental cholestasis , 1996, Journal of gastroenterology and hepatology.
[12] T. Roskams,et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.
[13] G. Farrell,et al. Downregulation of male‐specific cytochrome P450s 2C11 and 3A2 in bile duct–ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis , 1995, Hepatology.
[14] K. Zatloukal,et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[15] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[16] P. Palatini,et al. Pharmacokinetic drug interactions in liver disease: An update. , 2016, World journal of gastroenterology.
[17] R. Evans,et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. , 2004, Molecular pharmacology.
[18] C. Favre,et al. Inhibitory Effect of Short-Term Bile Duct Ligation on Hepatic Cytochrome P450 of Bile Acid-Depleted Rats , 2001, Pathobiology.
[19] Marco Migliorati,et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. , 2011, Biochimica et biophysica acta.
[20] H. Rogers,et al. Enzyme Inhibition , 1954, Nature.
[21] D. Nie,et al. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. , 2012, Biochemical pharmacology.
[22] R. Evans,et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] P. Pávek. Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions , 2016, Front. Pharmacol..
[24] G. Albertin,et al. Differential Effect of Liver Cirrhosis on the Pregnane X Receptor–Mediated Induction of CYP3A1 and 3A2 in the Rat , 2014, Drug Metabolism and Disposition.
[25] Kaoru Kobayashi,et al. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. , 2002, Biochemical pharmacology.
[26] K. Okazaki,et al. Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats. , 2008, World journal of gastroenterology.
[27] Yi-Tong Liu,et al. Drugs as CYP3A Probes, Inducers, and Inhibitors , 2007, Drug metabolism reviews.
[28] V. Tahan,et al. Time course of collagen peak in bile duct-ligated rats , 2011, BMC gastroenterology.
[29] T. Willson,et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] Li Wang,et al. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? , 2016, Annual review of pharmacology and toxicology.
[31] J. Villeneuve,et al. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. , 2000, Canadian journal of physiology and pharmacology.
[32] R. Evans,et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Orlando,et al. Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes , 2013, PloS one.
[34] Taosheng Chen,et al. Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk , 2016, Expert opinion on drug metabolism & toxicology.
[35] G. Hirschfield,et al. Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.
[36] P. Thomas,et al. Generation of specific antibodies and their use to characterize sex differences in four rat P450 3A enzymes following vehicle and pregnenolone 16alpha-carbonitrile treatment. , 2006, Archives of biochemistry and biophysics.
[37] G. Farrell,et al. Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. , 1984, The Australian journal of experimental biology and medical science.
[38] A. Baghdasaryan,et al. Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases , 2013, Clinics in liver disease.
[39] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[40] J. Boyer,et al. Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.
[41] Sabine Weiskirchen,et al. Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis , 2015, Journal of visualized experiments : JoVE.
[42] I. Dimauro,et al. A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue , 2012, BMC Research Notes.
[43] G. Wilkinson,et al. Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.